Register Login
Register to leave comments
  • News bot March 12, 2026, 8:46 p.m.

    📋 NEKTAR THERAPEUTICS (NKTR) - Financial Results

    Filing Date: 2026-03-12

    Accepted: 2026-03-12 16:45:08

    Event Type: Financial Results

    Event Details:

    NEKTAR THERAPEUTICS (NKTR) Reports the reporting period Financial Results NEKTAR THERAPEUTICS (NKTR) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: (9,769
    • Net Income: (36,079
    • EPS: $164
    • Cash and equivalents: 15116
      • 0165, a tumor necrosis factor receptor 2 (TNFR2) antibody, in multiple sclerosis. ●In February 2026, Nektar announced the successful closing of a public offering of its common stock, including the full exercise of underwriters’ option to purchase additional shares, raising $460 million in gross proceeds. ●In February 2026, Nektar presented new maintenance data from the REZOLVE
      • AD Phase 2b Study in atopic dermatitis, demonstrating durable and new responses with rezpegaldesleukin across key disease measurements with both monthly and quarterly dosing. ●In December 2025, Nektar announced topline results from the 36
      • week induction treatment period of the REZOLVE

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Current Assets Property Equipment Net 2.06K 3.41K $-1.35K -39.61%
    Current Assets Operating Lease Right Of Use Assets 2.94K 8.41K $-5.47K -65.04%
    Current Assets Other Assets 5.65K 4.65K $1.00K +21.54%
    Current Liabilities Accounts Payable 10.77K 11.56K $-790.00 -6.83%
    Current Liabilities Other Long Term Liabilities 8.62K 7.24K $1.38K +19.11%
    Operating Costs And Expenses Restructuring Impairment 1.36K 9.33K $-7.97K -85.42%
    Operating Costs And Expenses Total Operating Expenses 14.83K 195.33K $-180.51K -92.41%
    Nonoperating Income Expense Interest Income 2.94K 10.44K $-7.50K -71.81%
    Nonoperating Income Expense Total Other Income Expense 135.00 361.00 $-226.00 -62.60%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: NEKTAR THERAPEUTICS
    • Ticker Symbol: NKTR

Search

News categories